Talazoparib (BMN 673)

For research use only.

Catalog No.S7048 Synonyms: LT-673

90 publications

Talazoparib (BMN 673) Chemical Structure

Molecular Weight(MW): 380.35

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Size Price Stock Quantity  
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Talazoparib (BMN 673) has been cited by 90 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
Features Most potent and selective PARPi reported thus far.
Targets
PARP1 [1]
(Cell-free assay)
0.57 nM
In vitro

BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. BMN 673 demonstrates single-agent cytotoxicityin BRCA-1 mutant (MX-1, IC50 = 0.3 nM) and BRCA-2 mutant cells (Capan-1, IC50 = 5 nM). In contrast, in MRC-5 normal human fibroblastand other tumor cell lines with wild-type BRCA-1 and BRCA-2 genes, IC50 of BMN 673 ranges between 90 nM and 1.9 μM. [1] In cultured human cancer cells, BMN 673 also significantly enhances the cytotoxic efficacy of both Temozolomide and SN-38. Off-target molecular screening did not identify significant non-specific activity for this class of PARP inhibitors. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BR5FVB1-Akt MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2wMlEuOTByIH7N MWOyOE81QC95MjDo NWT4dIdVcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> MkDFNlYxPDd4OUe=
BR5FVB1-Akt MXXBdI9xfG:|aYOgRZN{[Xl? NXLWOYx5OC5zLUGwNEBvVQ>? NXzZU2lOPzJiaB?= M3vxfolv\HWlZYOgZZBweHSxc3nz MmrGNlYxPDd4OUe=
Capan-1 M{TGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYniN4dtUUN3ME2xOk4x6oDLwsJihKk2NjUkgJpCuW3DqA>? MnXmNlU5PjR3OUC=
MIA PaCa-2 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLWTWM2OD13OD6yN-KBkcLz4pEJPE4y6oDLwsXNxsA> NEXjO3EzPTh4NEW5NC=>
RD MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPiRYk5UUN3ME24Mlchdk1? Ml7hNlUzPjN3M{m=
Rh41 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr5clBKSzVyPUiuNUBvVQ>? MXmyOVI3OzV|OR?=
Rh18 M1O2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6wPGVKSzVyPUSuPUBvVQ>? Mme4NlUzPjN3M{m=
Rh30 NGGxdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\MbG1LUUN3ME2zNU4yKG6P NFqxTpozPTJ4M{WzPS=>
BT-12 M324S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XSOmlEPTB-4pEJNUwxODBibl2= M4fqNFI2OjZ|NUO5
CHLA-266 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHzTWM2OD8kgJmxMFAxOCCwTR?= MnvNNlUzPjN3M{m=
TC-71 NITmVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\DZppKSzVyPUOuO{BvVQ>? NHO1WnczPTJ4M{WzPS=>
CHLA-9 NGKxW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnkb3dKSzVyPUiuNkBvVQ>? M2H3V|I2OjZ|NUO5
CHLA-10 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3Xb2ZKSzVyPU[3Mlghdk1? NVvWTnlSOjV{NkO1N|k>
CHLA-258 M3i1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjMTWM2OD12Lk[gcm0> NWP4OFRCOjV{NkO1N|k>
SJ-GBM2 M{LSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWraSI1FUUN3ME2xOk4zKG6P NWXx[21[OjV{NkO1N|k>
NB-1643 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\ybmNSUUN3ME2xPE41KG6P NVX2TWRWOjV{NkO1N|k>
NB-EBc1 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hp[WlEPTB;MkWuPEBvVQ>? M13KcFI2OjZ|NUO5
CHLA-90 M{KxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PPW2lEPTB-4pEJNUwxODBibl2= Ml2wNlUzPjN3M{m=
CHLA-136 M36ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPaNoRRUUN3ME2xOE4zKG6P M3;iTlI2OjZ|NUO5
NALM-6 M4XmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LFbWlEPTB;NEmgcm0> NGn0XVQzPTJ4M{WzPS=>
COG-LL-317 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XGV2lEPTB;OT60JI5O Mmf5NlUzPjN3M{m=
RS4;11 M{njeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[wXWlEPTB;NUKuOkBvVQ>? M3\2UVI2OjZ|NUO5
MOLT-4 M2jyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrzWm9KSzVyPUG2MlYhdk1? NVOzO2dNOjV{NkO1N|k>
CCRF-CEM M2HoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3JSWZSUUN3ME22PVcvOyCwTR?= NHzrUWozPTJ4M{WzPS=>
Kasumi-1 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTd6Nj6yJI5O MVKyOVI3OzV|OR?=
Karpas-299 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO2TlI1UUN3ME23OU44KG6P NYTRR4FUOjV{NkO1N|k>
Ramos-RA1 NUHNSGFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;BNYdNUUN3ME22PE4{KG6P MV6yOVI3OzV|OR?=
DT40 NVfwRZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTRibl2= NXfXW|FUOjR|NU[4NVM>
DU145 M3nUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G1eWlEPTB;MUGgcm0> NIHpfG8zPDN3NkixNy=>
H209 NGfyN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLNUIhJUUN3ME2xMlchdk1? MXqyOFA4PzN3MB?=
H1048 NHHpUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwMjDuUS=> NUP4NFQ6OjRyN{ezOVA>
H524 NH2zTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLKeppKSzVyPUOuNUBvVQ>? MkTiNlQxPzd|NUC=
H1930 MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3vd4I6UUN3ME20MlEhdk1? Ml\MNlQxPzd|NUC=
H69 NYXhNI1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3vRYlDUUN3ME21MlIhdk1? NUXNOWNLOjRyN{ezOVA>
H2081 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ufm9KSzVyPU[uN{BvVQ>? M2TJc|I1ODd5M{Ww
H2107 M3PPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTdwMzDuUS=> NWi3N5pPOjRyN{ezOVA>
H1092 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG5[oRKUUN3ME24Mlkhdk1? M{LOflI1ODd5M{Ww
DMS-79 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\MOGlEPTB;OT6zJI5O NH;EWnozPDB5N{O1NC=>
H446 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUeyR2ZiUUN3ME2xN{BvVQ>? M{DjV|I1ODd5M{Ww
COR-L279 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXkZWhMUUN3ME2xOUBvVQ>? M163UlI1ODd5M{Ww

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved-PARP / cleaved-caspase3 / γ-H2AX; 

PubMed: 29158830     


Western Blot data testing protein expression after treatment with Olaparib, Niraparib, and Talazoparib on Brca1-deficient cell line in W0069 cells.

pKAP1 / pChk2 / pChk1; 

PubMed: 28947502     


Western blot images (representative from 3 independent experiments) showing the impact of a 24 hour pre-treatment with TAL ± TMZ on DNA damage signaling in U251 (MGMT-low) and T98G (MGMT-high) cells. 

PD-L1; 

PubMed: 28167507     


MDA-MDA-MB-231 and BT549 cells were treated with 10 μM olaparib or 10 nM talazoparib for 24 hours, and subjected to immunoblotting with the indicated antibodies. PD-L1 knockout (K/O) cells were included as a negative control. 

p-ATM; 

PubMed: 30472087     


Western blot analysis of the DNA damage sensors ATM, p-ATM (Ser1981), CHK1, p-CHK1 (Ser317), CHK2 and p-CHK2 (Thr68) in MV4-11 and HL-60 cells. GAPDH served as a loading control.

29158830 28947502 28167507 30472087
Growth inhibition assay
Cell viability; 

PubMed: 29158830     


Measured dose response curve and IC50 of Talazoparib in W780 and W0069 cells.

29158830
Immunofluorescence
cleaved PARP / 53BP1; 

PubMed: 28958991     


Cleaved-PARP and 53BP1 expression. Representative images with 10× objective from high-content imaging of control cells in the left column, and cells treated with veliparib, olaparib, and talazoparib in three right columns. 53BP1 expression is seen in: A, HCC1143; B, MDAMB231; and C, HCC1806. Blue represents nuclear staining and pink foci represent 53BP1 foci. Cleaved-PARP expression is seen in D, HCC1143 and E, HCC1806. Blue represents nuclear staining and green represents cleaved-PARP expression.

RAD51; 

PubMed: 30621214     


(A) MCF7 and (B) MCF7-T cells were treated with either 100 nM tamoxifen (Tamox) or 1 nM talazoparib (Talaz) for 72 h, alone and in combination. 24 h post treatment RAD51 foci formation assay was performed. Scale bar: 20 µm.

28958991 30621214
In vivo In rat pharmacokinetic studies, BMN 673 displays >50% oralbioavailability and pharmacokinetic properties that enable singledaily dosing. In MX-1 xenograft tumor model studies, daily oral dosingof BMN 673 significantly enhances the antitumor effects ofcytotoxic therapies in a dose-dependent manner. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: MX-1 model (BRCA-1 deficient)
  • Dosages: 0.33 mg/kg/day, once daily
  • Administration: Oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL warmed (99.9 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 380.35
Formula

 

C19H14F2N6O
 
CAS No. 1207456-01-6
Storage powder
in solvent
Synonyms LT-673

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04337970 Recruiting Drug: Talazoparib|Drug: Axitinib Kidney Cancer|Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma Memorial Sloan Kettering Cancer Center April 6 2020 Phase 1|Phase 2
NCT04134884 Recruiting Drug: Talazoparib|Drug: ASTX727 Metastatic Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Tumor Kathy Miller|Pfizer|Astex Pharmaceuticals Inc.|Van Andel Institute Stand Up to Cancer Team|Indiana University March 30 2020 Phase 1
NCT03974217 Recruiting Drug: Talazoparib Leukemia Dana-Farber Cancer Institute|Pfizer August 1 2019 Phase 1
NCT03901469 Recruiting Drug: ZEN003694|Drug: Talazoparib Triple Negative Breast Cancer Zenith Epigenetics|Pfizer June 26 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Which solvent do you recommend to dilute the inhibitor for in vivo study in mice?

  • Answer:

    BMN673 (S7048) can be dissolved in vehicle (10% DMAc, 6% Solutol, and 84% PBS) according to the paper: http://clincancerres.aacrjournals.org/content/19/18/5003.full. Quote from Method and Material section "Xenograft experiments: BMN 673 (various doses as indicated), or vehicle (10% DMAc, 6% Solutol, and 84% PBS) was administered by oral gavage"

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Talazoparib|Talazoparib ic50|Talazoparib price|Talazoparib cost|Talazoparib solubility dmso|Talazoparib purchase|Talazoparib manufacturer|Talazoparib research buy|Talazoparib order|Talazoparib mouse|Talazoparib chemical structure|Talazoparib mw|Talazoparib molecular weight|Talazoparib datasheet|Talazoparib supplier|Talazoparib in vitro|Talazoparib cell line|Talazoparib concentration|Talazoparib nmr|Talazoparib in vivo|Talazoparib clinical trial|Talazoparib inhibitor|Talazoparib DNA Damage inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID